Gold Falls Below $4,000 as Fed Rate Hike Fears Grow: Is the Precious Metals Bull Case Still Intact?

Gold prices fell below $4,000 per ounce Wednesday as stronger-than-expected U.S. inflation data and increasingly hawkish Federal Reserve commentary weighed on precious metals. The latest decline raises an important question for investors: Does the selloff signal a broader reversal in gold’s outlook, or could it present an opportunity for those focused on long-term economic uncertainty?

Spot gold declined approximately 1.1% to $3,987 per ounce during Wednesday afternoon trading, extending Tuesday’s nearly 3% drop. December gold futures settled near $4,000, highlighting the volatility that has emerged as investors reassess the direction of interest rates.

The selling followed Tuesday’s Consumer Price Index report, which showed U.S. consumer prices rising 0.4% in October, exceeding economists’ expectations for a 0.3% increase. Core inflation, excluding food and energy, also increased 0.3%, reinforcing concerns that price pressures remain persistent.

Federal Reserve officials have subsequently signaled that additional monetary tightening may be necessary. Investors now anticipate another interest-rate increase in December, with growing speculation that policymakers could consider a larger-than-usual adjustment.

Higher interest rates typically create challenges for gold because the metal does not generate interest or dividends. As Treasury yields rise, income-producing investments become relatively more attractive, while a stronger U.S. dollar makes gold more expensive for international buyers.

However, the longer-term investment case for precious metals extends beyond the Federal Reserve’s next decision.

The United States continues to face substantial federal debt, persistent budget deficits, and rising interest expenses. These structural challenges have contributed to investor interest in gold as a potential store of value and portfolio diversifier.

The recent midterm elections have added another layer of uncertainty, with divided government potentially making significant fiscal reforms more difficult to achieve.

Although political gridlock can sometimes restrain new spending initiatives, it can also complicate efforts to address existing budget obligations and long-term debt growth.

For investors concerned about fiscal sustainability, gold remains one potential way to diversify exposure to traditional financial assets.

Central bank purchases also continue to influence the precious metals market. Gold reserves can help countries diversify their holdings, reducing reliance on individual currencies and providing an asset that does not depend on another institution’s ability to repay debt.

These longer-term factors may help support demand even when short-term monetary policy creates selling pressure.

The implications extend beyond physical bullion to publicly traded mining companies, particularly smaller exploration and development-stage businesses.

When gold prices rise, the potential economics of certain mineral deposits can improve, attracting investor interest and potentially increasing the value of undeveloped resources.

However, mining equities carry risks that differ significantly from owning gold directly. Exploration results, project financing, permitting requirements, operating costs, and management execution can all influence shareholder returns.

Resolution Minerals (RML) illustrates the type of smaller resource-development business investors may evaluate when assessing opportunities across the mining sector.

For companies at this stage, the quality of mineral assets and the ability to advance projects remain critical regardless of daily movements in commodity prices.

Silver presents another consideration. Unlike gold, silver has substantial industrial applications, including electronics, solar energy, and electrical infrastructure, making its price sensitive to both investment demand and economic activity.

Despite the latest pullback, gold’s longer-term outlook remains closely tied to inflation expectations, interest rates, central bank demand, and confidence in government finances.

A sustained period of higher real interest rates could create further downside pressure, while renewed economic uncertainty or stronger investment demand could support a recovery.

For investors, the recent selloff serves as a reminder that even traditional safe-haven assets can experience sharp declines.

Whether gold’s weakness becomes a buying opportunity will depend on how monetary policy evolves and whether the structural forces supporting precious metals demand remain intact.

Altius Minerals to Acquire TNR Gold in C$122 Million Deal, Expanding Copper and Lithium Royalty Portfolio

Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF) has announced a definitive agreement to acquire TNR Gold Corp. (TSXV: TNR) in a transaction valued at approximately C$122 million, expanding its exposure to major copper and lithium projects in Argentina while providing TNR shareholders with a substantial premium.

The agreement, announced November 11, represents another example of consolidation in the mining sector as companies seek long-term exposure to critical minerals essential for electrification, energy infrastructure, and industrial development.

Under the terms of the transaction, TNR shareholders will receive 0.0072 Altius common shares and 0.25 shares of a newly formed company, TNR SpinCo, for each TNR share held.

Based on Altius’ November 10 closing share price, the consideration represents approximately C$0.48 per TNR share, a premium of roughly 60% over TNR’s previous closing price.

The estimated transaction value includes approximately C$97 million in Altius shares and C$25 million attributed to TNR SpinCo.

For Altius, the acquisition provides additional royalty interests in several significant mineral projects, including the Los Azules copper project, Mariana lithium project, and Josemaria copper-gold project in Argentina.

The Los Azules project is among the most important assets involved in the transaction. Owned by McEwen Copper, the development-stage project is targeting a final investment decision by mid-2027 and initial production in 2030.

A recently completed feasibility study outlined average annual production of approximately 148,000 tonnes of copper cathode over a projected 21-year mine life.

The royalty interest being acquired represents an effective 0.36% net smelter return royalty on Los Azules.

Altius will also increase its exposure to the Mariana lithium project, operated by Ganfeng Lithium. The project has begun production and is ramping toward a target of 20,000 tonnes of lithium carbonate equivalent annually, with the operator considering a potential expansion to 40,000 tonnes.

The effective royalty interest being acquired in Mariana is approximately 1.35%.

These assets support Altius’ strategy of acquiring royalty interests in long-life mineral projects rather than directly operating mines.

Under a royalty model, companies generally receive a percentage of revenue or production from mining operations without bearing the same direct operating expenses as mine owners.

This approach can provide exposure to commodity prices and production growth while reducing certain operational risks, although royalty holders remain dependent on successful project development and sustained mining activity.

The transaction also includes a restructuring of TNR’s existing assets.

TNR SpinCo will retain the Shotgun Gold Project in Alaska, allowing shareholders to maintain exposure to its exploration potential independently of the copper and lithium royalty portfolio.

Altius will retain a 0.5% net smelter return royalty on Shotgun and plans to invest C$2.2 million in SpinCo following the transaction, increasing its ownership interest to approximately 19.9%.

For mining investors, the deal highlights the value that established royalty companies may place on smaller businesses holding interests in strategically important mineral projects.

Copper demand remains closely linked to electricity infrastructure, renewable energy systems, transportation, and industrial modernization. Lithium continues to play a major role in rechargeable batteries and energy storage technologies.

However, both commodities are exposed to price fluctuations, changing supply conditions, and project development risks.

The acquisition is expected to close in the first quarter of 2027, subject to shareholder, court, regulatory, and stock-exchange approvals. TNR shareholders are expected to vote on the transaction in December.

While the proposed 60% premium offers an immediate indication of the value Altius places on TNR’s assets, the longer-term investment case depends on the successful advancement of the underlying mining projects.

For small-cap investors, the transaction illustrates how royalty interests and early-stage mineral assets can attract acquisition interest from larger companies seeking long-term exposure to critical resources.

The Beachbody Company (BODI) – Lower Cost Base, Greater Earnings Potential


Wednesday, November 11, 2026

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 Operating Results. The company reported Q3 revenue of $45.2 million, largely in line with our $46.0 million estimate. Adjusted EBITDA of $6.4 million exceeded our $4.5 million forecast by 41% and was supported by more efficient marketing spending. Notably, Q3 marked the 12th consecutive quarter of positive adjusted EBITDA.

Nutrition-First Strategy. While retail expansion is progressing more slowly than anticipated, Shakeology has reached 181 Sprouts and 481 Vitamin Shoppe stores. Additionally, the company is approximately a year ahead of schedule with its product innovation pipeline, introducing new offerings under its established Shakeology, P90X, and INSANITY brands.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Summit Midstream Corp (SMC) – Higher Volumes Lift Outlook; Increasing Estimates


Wednesday, November 11, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter 2026 Financial Results. Summit Midstream Corporation reported revenue of $183.0 million, up 24.6% year over year and 18.1% sequentially. Net income attributable to common shareholders was approximately $8.2 million, or $0.58 per diluted share, compared with a loss of $1.6 million, or $(0.13) per share, a year ago and income of $1.6 million, or $0.11 per share, in the prior quarter. Adjusted EBITDA increased 7.9% year over year and 16.4% sequentially to $70.7 million. Distributable cash flow declined to $32.6 million from $36.7 million a year ago and $36.8 million in the prior quarter, while free cash flow decreased to $5.2 million from $16.7 million and $9.4 million, respectively.

Guidance Increased. Management raised its 2026 adjusted EBITDA guidance to $250 million to $260 million and from $235 million to $255 million, reflecting stronger producer activity and higher throughput. Rockies Segment adjusted EBITDA increased 32% sequentially to $40.0 million, supported by 51 new well connections. Double E throughput increased 17% to a record 1,002 MMcf/d, and Summit reached a final investment decision on its Mainline Compression Expansion. With seven active rigs and approximately 140 drilled but uncompleted wells behind its systems, management anticipates connecting 200 to 250 wells in 2027.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – A Third Homebuilder Contract


Wednesday, November 11, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Contract. SKYX Platforms announced the third homebuilder contract signed since the merger with Deako. The recent contract with Stone Martin Home calls for Deako to supply approximately 70,000 units of advanced and smart home technologies to Stone Martin for more than 850 homes in Georgia and Alabama through 2027. Momentum continues to snowball, in our view.

Stone Martin. Stone Martin Builders is a prominent Southeast homebuilder that has been developing communities across Alabama and Georgia for over 20 years. Significantly, Stone Martin homes include Deako smart home and lighting as part of a full smart home package.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – OCU400 Marketing Agreement For Australia, New Zealand, and ASEAN Announced


Wednesday, November 11, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Marketing Agreement For OCU400 Adds Pacific Territories. Ocugen announced a marketing agreement with Celairis Therapeutics Holdings Pty Ltd for commercialization of OCU400 in Australia, New Zealand, Taiwan, and Asian territories known as ASEAN (Association of Southeast Asian Nations). The agreement includes licensing fees, milestones, sales royalties, and a profit split. This is the third OCU400 agreement to add ex-US territories.

New Populations Are Covered. Celairis is a Sydney, Australia-based biopharmaceutical company that licenses, develops, and markets medicines. The licensed territories include Australia, New Zealand, Taiwan, and the ASEAN countries (Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Brunei, Vietnam, Myanmar, Cambodia, and Timor). These new territories add an estimated 725 million people to regions within OCU400’s marketing reach.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FreightCar America (RAIL) – Third Quarter 2026 Review and Outlook


Wednesday, November 11, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter FY 2026 Financial Results. RAIL reported an adjusted net loss to common stockholders of $9.5 million, or $(0.28) per diluted share, versus adjusted net income of $7.8 million, or $0.24 per share, during the prior-year period. Revenue fell 52.3% to $76.5 million from $160.5 million, as railcar deliveries declined to 662 from 1,304. Gross margin fell to 8.8% from 15.1% on lower manufacturing volumes and reduced fixed-cost absorption. Adjusted EBITDA declined to $0.1 million from $15.9 million in the third quarter of FY 2025.

FY 2026 Guidance. Management reaffirmed its FY 2026 guidance, initially announced on October 19. Railcar deliveries are expected to range from 3,100 to 3,300, revenue from $370 million to $410 million, and adjusted EBITDA from $15 million to $19 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MaxCyte to Acquire Akron Bio for $151.8 Million, Nearly Doubling Revenue Base in Cell Therapy Expansion

MaxCyte (NASDAQ: MXCT) announced Tuesday that it has agreed to acquire Akron BioProducts for approximately $151.8 million, significantly expanding its position in the rapidly developing cell and gene therapy manufacturing market. The transaction is expected to nearly double MaxCyte’s revenue base while accelerating its path toward profitability.

The acquisition brings together two companies providing essential technologies and materials used in developing and manufacturing advanced cell therapies. MaxCyte specializes in cell-engineering platforms, while Akron Bio supplies critical manufacturing materials used throughout the cell therapy production process.

Under the agreement, MaxCyte will pay $105 million in cash, issue approximately 20.6 million shares valued at $26.8 million, and make an additional $20 million in guaranteed deferred payments during 2028 and 2029. The transaction is expected to close before the end of 2026, subject to customary conditions.

Akron Bio, headquartered in Boca Raton, Florida, supplies pharmaceutical-grade reagents and manufacturing materials used in cell therapy development. Its products include growth factors, cytokines, specialized media, and human plasma-derived materials that support the production of therapeutic cells.

The acquisition expands MaxCyte’s capabilities beyond its existing non-viral cell-engineering technology, allowing the combined company to support additional stages of the manufacturing process, including both viral and non-viral approaches.

For biotechnology developers, these materials are essential to producing consistent, high-quality cell therapies that meet regulatory requirements.

The combined business is expected to support more than 100 clinical programs and five commercially approved therapies, strengthening MaxCyte’s exposure to treatments already generating commercial manufacturing demand.

Akron Bio is projected to generate approximately $28 million in revenue and between $7 million and $8 million in earnings before interest, taxes, depreciation, and amortization (EBITDA) during 2026.

Importantly, Akron also brings positive cash flow and recurring revenue from manufacturing materials, potentially providing greater financial stability as MaxCyte expands its operations.

MaxCyte expects the combination to reduce annual cash burn to less than $10 million in 2027, compared with the higher spending typically associated with developing and commercializing emerging biotechnology platforms.

The company has also secured a credit facility of up to $75 million from MidCap Financial to help support the acquisition and future operations.

The announcement coincided with MaxCyte’s third-quarter earnings results, which showed revenue increasing 49% year over year to $10.2 million. Core business revenue rose 27%, while revenue from strategic platform licensing programs reached $2 million.

MaxCyte also raised its standalone full-year 2026 revenue guidance to at least $34.5 million, reflecting improving demand across its existing business.

For small-cap biotechnology investors, the transaction illustrates how companies can pursue growth by expanding beyond a single technology platform into complementary products and services.

Cell and gene therapies represent a growing area of medicine, but their development requires specialized equipment, manufacturing materials, and extensive regulatory oversight.

Companies supplying these essential components can potentially benefit from industry expansion without assuming all the clinical development risks associated with individual drug candidates.

The acquisition also creates opportunities for MaxCyte to introduce Akron’s products to existing customers, potentially increasing revenue from established relationships.

However, investors will need to monitor integration expenses, debt obligations, and shareholder dilution associated with the transaction.

The combined company is expected to have approximately $40 million to $45 million in cash and investments at closing, providing liquidity as management works toward profitability.

With more cell therapies advancing through clinical trials and into commercial production, MaxCyte is positioning itself to participate in a broader portion of the manufacturing process.

The acquisition marks a significant strategic shift for the company, transforming it from a specialized cell-engineering technology provider into a more comprehensive supplier supporting the development and commercialization of next-generation therapies.

Take a moment and take a look at Noble’s Research Analyst Robert LeBoyer’s biotechnology and life sciences research coverage.

Superior Group of Companies (SGC) – A Stronger Foundation for 2027


Tuesday, November 10, 2026

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q3 Results. The company reported Q3 revenue of $146.0 million, up 5.4% year over year and above our $143.1 million estimate, supported by growth in Branded Products and Contact Centers. Adj. EBITDA, including stock-based compensation, was $7.6 million, below our $8.6 million estimate. Moreover, Healthcare Apparel inventory and credit charges largely offset profitability gains in the other segments.

Underlying Business Trends. Branded Products revenue increased 8.2% to $92.1 million, while segment-adjusted EBITDA rose 30.8% on higher customer volumes and improved pricing. Contact Centers returned to revenue growth, up 6.9%, with adjusted EBITDA advancing 22.1%. Healthcare Apparel posted a $0.5 million adjusted EBITDA loss, reflecting a $4.0 million inventory write-down and approximately $1.0 million in customer credit losses.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Summit Midstream Corp (SMC) – Strong Volume Growth Lifts Outlook


Tuesday, November 10, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter 2026 Financial Results. Summit reported revenue of $183.0 million, up 24.6% year over year. Net income attributable to Summit increased to $8.2 million, or $0.58 per diluted share, versus a loss of $1.6 million, or $(0.13) per share, a year ago. Adjusted EBITDA rose 7.9% year over year and 16.4% sequentially to $70.7 million. Revenue, Adjusted EBITDA, and EPS exceeded our estimates of $158.0 million, $65.1 million, and $0.34, respectively. Distributable cash flow declined to $32.6 million from $36.7 million, while free cash flow fell to $5.2 million from $16.7 million, partly reflecting higher cash interest and Double E investment.

Guidance Increased. Management raised 2026 Adjusted EBITDA guidance to $250–$260 million from $235–$255 million, implying fourth-quarter EBITDA of $64.4–$74.4 million. Rockies segment Adjusted EBITDA increased 32% sequentially to $40.0 million, supported by 51 new well connections and higher liquids throughput. Results also benefited from $3.7 million of commercial billing settlements. With seven active rigs and approximately 140 drilled but uncompleted wells, Summit anticipates 200–250 well connections in 2027.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Star Equity Holdings, Inc. (STRR) – A Tuck-in for Hudson


Tuesday, November 10, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Acquisition. Last week, Star Equity announced that its Hudson Talent Solutions business acquired Cornerstone RPO LLC, a recruitment process outsourcing (“RPO”) provider based in Richmond, Virginia. The transaction closed on November 2, 2026. Cornerstone will operate as part of HTS within Star’s Business Services division. We view this bolt-on as part of HTS’s strategy as a global total talent solutions provider.

Details. At closing, Star paid the sellers $500,000 in cash and $250,000 in a promissory note. Up to an additional $1.5 million of contingent earnout is possible if the firm hits certain revenue milestones, with the entire payout payable if Cornerstone hits $20 million of revenue over 36 months. We see a clear opportunity to grow Cornerstone’s existing client engagements into larger, longer-term programs through HTS’s enterprise RPO, talent advisory, and TalentFusion capabilities.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – A Solid Third Quarter


Tuesday, November 10, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Kratos reported another strong quarter with revenue at the midpoint of guidance and adjusted EBITDA exceeding the high end of guidance. The Company’s third-quarter results reflect Kratos’ position as a leading defense technology, hardware, software, and systems company, aligned with the Department of War’s priorities and reindustrialization efforts, in our view. 

3Q26 Results. Third quarter 2026 revenues of $471.8 million increased by $124.2 million year-over-year. We had projected $462 million. KGS revenue grew 52.5% to $397.2 million, while KUS segment revenue declined to $74.6 million from $87.2 million due to the absence of a $16.1 million Valkyrie sale completed last year. Adjusted EBITDA was $50.9 million versus $30.8 million. Kratos reported adjusted earnings per share of $0.24 for the third quarter of 2026, compared to $0.14 for the third quarter of 2025. We had projected $41 million and $0.22/sh, respectively.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FreightCar America (RAIL) – Outlook Reaffirmed Despite Weak Third Quarter


Tuesday, November 10, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Richard Magnusen, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter FY 2026 Financial Results. RAIL generated a 3Q FY26 adjusted net loss to common stockholders of $9.5 million, or $(0.28) per share, compared to adjusted net income of $7.8 million, or $0.24 per share, during the prior-year period. We had projected a net loss of $4.2 million, or ($0.13) per share. Gross margin as a percentage of revenue amounted to 8.8% compared to 15.1% in 3Q FY 2025. Revenue and rail car deliveries declined to $76.5 million and 662, compared to $160.5 million and 1,304 during the prior-year period. We had forecast revenue of $76.1 million and deliveries of 662. Adj. EBITDA amounted to $0.1 million compared to $15.9 million in 3Q FY 2025 and our estimate of $0.0 million. We had projected a higher gross margin. FCF for 3Q was $25.0 million compared to $2.2 million during the prior-year period.

Updated FY 2026 Guidance. Management reaffirmed its FY 2026 guidance provided on October 19. Railcar deliveries are expected to be in the range of 3,100 to 3,300, revenue in the range of $370 to $410 million, and adj. EBITDA in the range of $15 to $19 million. Reaffirmed guidance implies a meaningful fourth-quarter recovery in adjusted EBITDA to $10.5 million to $14.5 million, supported by higher deliveries and improved manufacturing profitability.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.